Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors
The invention provides a chemical entity of Formula (I): wherein R 1 , R 2 , X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.
1 . A compound, which is (2S)-4-[(3,5-Dichlorophenyl) carbonyl]-2-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}morpholine.
2 . A compound, which is (2S)-4-[3-Bromo-4-(trifluoromethyl)benzoyl]-2-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}morpholine.
3 . A compound, which is (2S)-4-(3-Bromo-4,5-difluorobenzoyl)-2-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}morpholine.
4 . A pharmaceutical composition comprising a pharmaceutically acceptable excipient; and an effective amount of the compound of claim 1 .
5 . A method of inhibiting PDE2 activity, comprising exposing PDE2 to an effective amount of the compound of claim 1 .
6 . A pharmaceutical composition comprising a pharmaceutically acceptable excipient; and an effective amount of the compound of claim 2 .
7 . A method of inhibiting PDE2 activity, comprising exposing PDE2 to an effective amount of the compound of claim 2 .
8 . A pharmaceutical composition comprising a pharmaceutically acceptable excipient; and an effective amount of the compound of claim 3 .
9 . A method of inhibiting PDE2 activity, comprising exposing PDE2 to an effective amount of the compound of claim 3 .